Published in Cancer Weekly, April 22nd, 2003
The Phase I clinical trial at the IU Cancer Center uses extracranial stereotactic radioablation (SRA) as a potential new treatment for hepatocelluar carcinoma, a cancer that originates in the liver, or for liver metastasis from other sites.
The technique evaluates the effects of escalating doses of radiation, which delivers highly focused, precisely targeted, radiation to destroy tumors with minimal damage to surrounding health tissues.
For this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-04-22)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.